Transparency Market Research Anxiety Disorders and Depression Treatment Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020
Published Date 26-Sep-2014
111 Page Report
Buy Now
Request Sample
Press Release Anxiety Disorders and Depression Treatment Market Expected to Reach USD 18.2 Billion Globally in 2020:Transparency Market Research Transparency Market Research State Tower, 90, State Street, Suite 700. Albany, NY 12207 United States www.transparencymarketresearch.com sales@transparencymarketresearch.com
Anxiety Disorders and Depression Treatment Market
REPORT DESCRIPTION
Anxiety Disorders and Depression Treatment Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020 According to a new market report published by Transparency Market Research “Anxiety Disorders and Depression Treatment Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020”, the global anxiety disorders and depression treatment market was valued at USD 22.5 billion in 2013 and is expected to reach USD 18.2 billion in 2020, at a CAGR of (1.25%) from 2014 to 2020. Browse Anxiety Disorders and Depression Treatment Market Report with Full TOC at http://www.transparencymarketresearch.com/anxiety-disorders-depression-treatments.html Anxiety is a biological reaction to stress, trauma and fear, which can be experienced by anyone in their lifetime, whereas depression is a mental state of low mood and aversion to daily activities that can affect an individual’s feelings, thoughts, sense of well-being and behavior. Depression affects 10% to 15% men and about 10% to 25% women. According to the World Health Organization (WHO), to date, over 350 million people have been affected by depression globally. The Anxiety and Depression Association of America revealed that at present approximately 40 million people in the U.S. are suffering from anxiety disorder and treating these patients costs around USD 42 billion each year. Thus, high prevalence of anxiety disorders and depression helped the market to transform itself into a billion dollar industry. However, the current scenario indicates that the overall anxiety disorders and depression treatment market would decline due to patent expiry of major antidepressants, weak pipeline of novel drugs and increasing number of generic drug variants. The anxiety disorders and depression treatment market has been segmented based on the drug classes commonly used for the treatment of various types of anxiety disorders and depression such as selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tetracyclic antidepressants (TeCA), monoamine oxidase inhibitors (MAOIs), benzodiazepines, atypical antipsychotics, anticonvulsants and beta blockers. SNRIs accounted for the largest share of over 30% of the depression treatment market in 2013. However, the segment is expected to witness a decline in revenue in the near future, reporting a CAGR of 14.2% from 2012 to 2016 and a CAGR of 4.3% from 2016 to 2020. Increasing influx of generic formulations as well as patent expiry of
Transparency Market Research
2
Anxiety Disorders and Depression Treatment Market
leading branded formulations such as Cymbalta, Lexapro and Effexor XR are some of the major factors that would negatively affect the growth of the segment. Moreover, with the loss of patent exclusivity, generics would offer physicians a broad range of affordable medications to prescribe, thereby significantly reducing the overall size of the anxiety disorders and depression treatment market. Hence, the future growth of the market would depend on commercialization of novel drugs for new indications. Major pipeline drugs identified and expected to be launched during the forecast period from 2014 to 2020 include Brintellix [(Vortioxetine-Lu AA21004) (Lundbeck and Takeda)], Brexpiprazole [(OPC-34712) (Otsuka)] and ALKS-5461 [(FDC-buprenorphine and samidorphan) (Alkermes plc)]. The positive clinical trial outcomes of these drugs and anticipated commercialization during the forecast period are expected to fuel the growth of antidepressants and anxiolytic drugs market in the near future. Geographically, North America accounted for the largest share of the anxiety disorders and depression treatment market in 2013 (over 35%). The U.S. accounted for the highest share of the revenue for each drug class due to the presence of one or more branded formulations that influenced the market dynamics significantly. However, the anxiety disorders and depression treatment market in the U.S. is currently saturated due to the presence of cheap generic products and several antidepressant drugs available on prescription for the same indication. Hence, the region is expected to witness a negative CAGR throughout the forecast period from 2014 to 2020. Asia Pacific is estimated to witness an appreciable growth rate (0.02%) due to various factors such as positive marketing approval for novel medicines, growing geriatric population and presence of a large population base in the region. Additionally, strong economic growth in countries such as China, Japan, New Zealand and Australia would contribute to the growth of the market in Asia Pacific. The market displays intense competitive rivalry among existing players, as currently the market for antidepressant and anxiolytic drugs is highly fragmented comprising both large and small manufacturers. Major market players include AstraZeneca plc, Eli Lilly and Company, Forest Laboratories, Inc., H. Lundbeck A/S, GlaxoSmithKline plc, Johnson & Johnson and Merck & Co., Inc. Eli Lilly and Company held the largest share of over 30% of the total anxiety disorders and depression treatment market in 2013. Product efficacy, differentiation, safety, well-developed distribution networks, and supply capabilities played a major role in determining the market position of the company. The global anxiety disorders and depression treatment market has been segmented as follows:
Transparency Market Research
3
Anxiety Disorders and Depression Treatment Market
Anxiety Disorders and Depression Treatment Market, by Drug Class •
Selective Serotonin Reuptake Inhibitors (SSRIs)
•
Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
•
Atypical Antipsychotics
•
Tricyclic Antidepressants (TCAs)
•
etracyclic Antidepressants (TeCAs)
•
Monoamine Oxidase inhibitors (MAOIs)
•
Benzodiazepines
•
Beta-Blockers
•
Anticonvulsants
Anxiety Disorders and Depression Treatment Market, by Geography • • • •
North America Europe Asia-Pacific Rest of the World (RoW)
Browse Anxiety Disorders and Depression Treatment Market Report with Full TOC at http://www.transparencymarketresearch.com/anxiety-disorders-depression-treatments.html
TABLE OF CONTENT
Transparency Market Research
4
Anxiety Disorders and Depression Treatment Market
Chapter 1 Introduction 1.1 Report Description 1.2 Market Segmentation 1.3 Research Methodology 1.4 Assumptions
Chapter 2 Executive Summary 2.1 Market Snapshot: Global Anxiety Disorders and Depression Treatment Market 2.2 Comparative Analysis: Global Anxiety Disorders and Depression Treatment Market, By Geography, 2013 and 2020 (Value %)
Chapter 3 Global Anxiety Disorders and Depression Treatment Market Overview 3.1 Market Dynamics and Overview 3.2 Market Drivers 3.2.1 Rising geriatric population expected to boost market growth 3.2.2 Greater efficacy and reduced side effects of drugs in various classes likely to drive market growth 3.2.3 Escalating prevalence of depression and anxiety disorders likely to contribute to market growth 3.3 Market Restraints 3.3.1 Patent expirations of major drugs during the forecast period expected to impede market growth 3.3.2 Dry pipeline of novel drugs is hindering market growth 3.3.3 Drug resistant-mental disorders likely to challenge augmentation of the market
Transparency Market Research
5
Anxiety Disorders and Depression Treatment Market
3.3.4 Increasing number of generic drug variants might negatively affect market growth 3.4 Market Opportunities 3.4.1 Improving distribution network in budding economies 3.4.2 Development of herbal remedies 3.5 Porter’s Five Forces Analysis 3.5.1 Bargaining Power of Suppliers 3.5.2 Bargaining Power of Buyers 3.5.3 Threat of Substitutes 3.5.4 Threat of New Entrants 3.5.5 Competitive Rivalry 3.6 Event Impact Analysis 3.7 Market Attractiveness Analysis: Global Anxiety Disorder and Depression Treatment Market, by Geography 3.8 Regulatory Framework 3.9 Market Share Analysis: Global Anxiety Disorders and Depression Treatment Market, by Key Players, 2013 (Value %)
Chapter 4 Global Anxiety Disorders and Depression Treatment Market, by Drug Class 4.1 Overview 4.1.1 Global Anxiety Disorder and Depression Treatment Market Revenue, by Condition, 2012 – 2020 (USD Million) 4.1.2 Global Anxiety Disorders Treatment Market Revenue, by Drug Class, 2012 – 2020 (USD Million)
Transparency Market Research
6
Anxiety Disorders and Depression Treatment Market
4.1.3 Global Depression Treatment Market Revenue, by Drug Class, 2012 – 2020 (USD Million) 4.2 Selective Serotonin Reuptake Inhibitors (SSRIs) 4.2.1 Global SSRIs Market Revenue, by Anxiety Disorders, 2012 – 2020 (USD Million) 4.2.2 Global SSRIs Market Revenue, by Depression, 2012 – 2020 (USD Million) 4.3 Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) 4.3.1 Global SNRIs Market Revenue, by Anxiety Disorders, 2012 – 2020 (USD Million) 4.3.2 Global SNRIs Market Revenue, by Depression, 2012 – 2020 (USD Million) 4.4 Atypical Antipsychotics 4.4.1 Global Atypical Antipsychotics Market Revenue, by Anxiety Disorders, 2012 – 2020 (USD Million) 4.4.2 Global Atypical Antipsychotics Market Revenue, by Depression, 2012 – 2020 (USD Million) 4.5 Tricyclic Antidepressants (TCAs) 4.5.1 Global TCAs Market Revenue, by Anxiety Disorders, 2012 – 2020 (USD Million) 4.5.2 Global TCAs Market Revenue, by Depression, 2012 – 2020 (USD Million) 4.6 Tetracyclic Antidepressants (TeCAs) 4.6.1 Global TeCAs Market Revenue, by Anxiety Disorders, 2012 – 2020 (USD Million) 4.6.2 Global TeCAs Market Revenue, by Depression, 2012 – 2020 (USD Million) 4.7 Monoamine Oxidase inhibitors (MAOIs) 4.7.1 Global MAOIs Market Revenue, by Anxiety Disorders, 2012 – 2020 (USD Million) 4.7.1.1 Global MAOIs Market Revenue, by Depression, 2012 – 2020 (USD Million) 4.8 Benzodiazepines 4.8.1 Global Benzodiazepines Market Revenue, by Anxiety Disorders, 2012 – 2020 (USD Million)
Transparency Market Research
7
Anxiety Disorders and Depression Treatment Market
4.8.2 Global Benzodiazepines Market Revenue, by Depression, 2012 – 2020 (USD Million) 4.9 Beta-Blockers 4.9.1 Global Beta-Blockers Market Revenue, by Anxiety Disorders, 2012 – 2020 (USD Million) 4.10 Anticonvulsants 4.10.1 Global Anticonvulsants Market Revenue, by Anxiety Disorders, 2012 – 2020 (USD Million)
Chapter 5 Global Anxiety Disorders and Depression Treatment Market, Pipeline Analysis 5.1 Overview 5.2 Brintellix (Vortioxetine - Lu AA21004) 5.2.1 Global Brintellix Market Revenue, 2014 – 2020 (USD Million) 5.3 Brexpiprazole (OPC-34712) 5.3.1 Global Brexipiprazole Market Revenue, 2016 – 2020 (USD Million) 5.4 ALKS-5461 5.4.1 Global ALKS-5461 Market Revenue, 2016 – 2020 (USD Million)
Chapter 6 Global Anxiety Disorders and Depression Treatment Market, by Geography 6.1 Overview 6.1.1 Global Anxiety Disorders and Depression Treatment Market Revenue, by Geography, 2012 – 2020 (USD Million) 6.1.2 Global Anxiety Disorders Treatment Market Revenue, by Geography, 2012 – 2020 (USD Million) 6.2 North America
Transparency Market Research
8
Anxiety Disorders and Depression Treatment Market
6.2.1 North America Anxiety Disorders and Depression Treatment Market Revenue, 2012 - 2020 (USD Million) 6.3 Europe 6.3.1 Europe Anxiety Disorders and Depression Treatment Market Revenue, 2012 - 2020 (USD Million) 6.4 Asia Pacific 6.4.1 Asia Pacific Anxiety Disorders and Depression Treatment Market Revenue, 2012 - 2020 (USD Million) 6.5 Rest of the World (RoW) 6.5.1 RoW Anxiety Disorders and Depression Treatment Market Revenue, 2012 - 2020 (USD Million)
Chapter 7 Recommendations 7.1 Emphasis on Developing Novel and Combination Products 7.2 Targeting Emerging Economies (China, Singapore, Brazil, Dubai, India, South Africa and Mexico) for Marketing Generic Pharmaceuticals 7.3 Strategic Partnership with Biopharmaceutical Organizations
Chapter 8 Company Profiles 8.1 AstraZeneca PLC 8.1.1 Company Overview 8.1.2 Financial Overview 8.1.3 Product Portfolio 8.1.4 Business Strategies
Transparency Market Research
9
Anxiety Disorders and Depression Treatment Market
8.1.5 Recent Developments 8.2 Eli Lilly and Company 8.2.1 Company Overview 8.2.2 Financial Overview 8.2.3 Product Portfolio 8.2.4 Business Strategies 8.2.5 Recent Developments 8.3 Forest Laboratories, Inc. 8.3.1 Company Overview 8.3.2 Financial Overview 8.3.3 Product Portfolio 8.3.4 Business Strategies 8.3.5 Recent Developments 8.4 GlaxoSmithKline plc 8.4.1 Company Overview 8.4.2 Financial Overview 8.4.3 Product Portfolio 8.4.4 Business Strategies 8.4.5 Recent Developments 8.5 H. Lundbeck A/S 8.5.1 Company Overview
Transparency Market Research
10
Anxiety Disorders and Depression Treatment Market
8.5.2 Financial Overview 8.5.3 Product Portfolio 8.5.4 Business Strategies 8.5.5 Recent Developments 8.6 Johnson & Johnson 8.6.1 Company Overview 8.6.2 Financial Overview 8.6.3 Product Portfolio 8.6.4 Business Strategies 8.6.5 Recent Developments 8.7 Merck & Co., Inc. 8.7.1 Company Overview 8.7.2 Financial Overview 8.7.3 Product Portfolio 8.7.4 Business Strategies 8.7.5 Recent Developments 8.8 Pfizer, Inc. 8.8.1 Company Overview 8.8.2 Financial Overview 8.8.3 Product Portfolio 8.8.4 Business Strategies
Transparency Market Research
11
Anxiety Disorders and Depression Treatment Market
8.8.5 Recent Developments 8.9 Sanofi-Aventis 8.9.1 Company Overview 8.9.2 Financial Overview 8.9.3 Product Portfolio 8.9.4 Business Strategies 8.9.5 Recent Developments
Browse Anxiety Disorders and Depression Treatment Market Report with Full TOC at http://www.transparencymarketresearch.com/anxiety-disorders-depression-treatments.html
About Us
Transparency Market Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forwardlooking insight for thousands of decision makers. We are privileged with highly experienced team of Analysts, Researchers and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Contact Transparency Market Research
Transparency Market Research
12
Anxiety Disorders and Depression Treatment Market
90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-552-3453 Email: sales@transparencymarketresearch.com Website: http://www.transparencymarketresearch.com/
Transparency Market Research
13